Anemia hemolítica autoinmune, reacción adversa a venetoclax

Carmen Carriles-Fernández; Lucía Ordóñez-Fernández; Aránzazu Arias-Martínez; Román Menárguez-Blanc; María Carmen Rosado-María

doi:10.7399/fh.11230

Anemia hemolítica autoinmune, reacción adversa a venetoclax

Carmen Carriles-Fernández, Lucía Ordóñez-Fernández, Aránzazu Arias-Martínez, Román Menárguez-Blanc, María Carmen Rosado-María

Resumen

Palabras clave

Texto completo:

PDF (English) PDF

Referencias

Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of CLL: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. 2008. Blood 111:5446.

European Medicines Agency. Ficha Técnica de Venetoclax (Venclyxto®) [consultado 30/01/2019]. Available at: https://www.ema.europa.eu/documents/productinformation/venclyxto- eparproductinformation_es.pdf

Anemia hemolítica autoinmune. Orphanet Urgencias 2017 [accessed 30/01/2019]. Available at: https://www.orpha.net/data/patho/Emg/Int/es/AnemiaHemoliticaAutoinm une_ES_es_EMG_ORPHA98375.pdf

Garratty G, Arndt PA. Drugs that have been shown to cause drug- induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 2014; 30:66.

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-778.

Informe de Posicionamiento Terapéutico de venetoclax (Venclyxto) en leucemia linfocítica crónica [accessed 30/01/2019]. Available at: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-venetoclax-Venclyxto-LLC.pdf

Schrier SL. Hemolytic anemia due to drugs and toxins. Uptodate, review on april 2019 [accessed 07/05/2019]. Available at: https://wwwuptodate.com.bvgcsalud.a17.csinet.es/contents/hemolytic- anemia-due-to-drugs-andtoxins?search=anemia%20hemol%C3%ADtica%20inducida%20por%20f%C3%A 1rmacos&sou ce=search_result&selectedTitle=1~38&usage_type=default&display_rank =1#H253178517

Lacerda MP, Guedes NR, Yamakawa PE, Pereira AD, Fonseca ARBMD, Chauffaille MLLF et al. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del (17p). Ann Hematol. 2017;96(9):1577-1578.

Sang M, Parikh SA. Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2017;12(1):29- 38.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30(2):239-45.

DOI: http://dx.doi.org/10.7399%2Ffh.11230